leadf
logo-loader
viewNemaura Medical Inc
(
NASDAQ:NMRD
)

Full interview: Nemaura Medical reveals details of upcoming European launch and recent patient feedback

Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020.

Dr Schaebsdau adds that recently, the Nemaura team presented positive feedback from its first patient-user experiences at the 55th Annual Meeting of the European Association for the Study of Diabetes.

Quick facts: Nemaura Medical Inc

Follow
NASDAQ:NMRD

Price: 6.88 USD

Market Cap: $160.36 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

BioVaxys preps for Phase 1 study as vaccine manufacturing partner reaches...

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) COO Kenneth Kovan tells Proactive that cancer vaccine manufacturing partner Bio Elpida has reached major milestones in the development of the bioproduction process for BVX-0918A, BioVaxys’ ovarian cancer vaccine. Kovan says the Lyon,...

1 day, 9 hours ago

2 min read